Skip Nav Destination
Issues
1 August 2017
-
Cover Image
Cover Image
The American Association for Cancer Research (AACR) launched the Genomics, Evidence, Neoplasia, Information, Exchange (GENIE) project in partnership with eight academic institutions to promote sharing of integrated clinical and genomic data from patients with cancer Data from participating centers include matched clinical and genomic data from a variety of tumor types that are harmonized and made accessible in the cBioPortal for Cancer Genomics Initial Project GENIE results suggest that more than 30% of tumors harbor potentially clinically actionable mutations This platform allows for integration of clinical data from electronic health records and increased statistical power to facilitate cancer precision medicine research The establishment of infrastructure to integrate genomic and clinical data may aid selection of therapeutic targets and biomarkers of treatment and response in patients with cancer to improve patient outcomes For details, please see the article by The AACR Project GENIE Consortium on page 818. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 2159-8274
EISSN 2159-8290
In This Issue
In the Spotlight
Review
Research Articles
Author Choice
AACR Project GENIE: Powering Precision Medicine through an International Consortium
The AACR Project GENIE Consortium; The AACR Project GENIE Consortium; Fabrice André; Monica Arnedos; Alexander S. Baras; José Baselga; Philippe L. Bedard; Michael F. Berger; Mariska Bierkens; Fabien Calvo; Ethan Cerami; Debyani Chakravarty; Kristen K. Dang; Nancy E. Davidson; Catherine Del Vecchio Fitz; Semih Dogan; Raymond N. DuBois; Matthew D. Ducar; P. Andrew Futreal; Jianjiong Gao; Francisco Garcia; Stu Gardos; Christopher D. Gocke; Benjamin E. Gross; Justin Guinney; Zachary J. Heins; Stephanie Hintzen; Hugo Horlings; Jan Hudeček; David M. Hyman; Suzanne Kamel-Reid; Cyriac Kandoth; Walter Kinyua; Priti Kumari; Ritika Kundra; Marc Ladanyi; Céline Lefebvre; Michele L. LeNoue-Newton; Eva M. Lepisto; Mia A. Levy; Neal I. Lindeman; James Lindsay; David Liu; Zhibin Lu; Laura E. MacConaill; Ian Maurer; David S. Maxwell; Gerrit A. Meijer; Funda Meric-Bernstam; Christine M. Micheel; Clinton Miller; Gordon Mills; Nathanael D. Moore; Petra M. Nederlof; Larsson Omberg; John A. Orechia; Ben Ho Park; Trevor J. Pugh; Brendan Reardon; Barrett J. Rollins; Mark J. Routbort; Charles L. Sawyers; Deborah Schrag; Nikolaus Schultz; Kenna R Mills Shaw; Priyanka Shivdasani; Lillian L. Siu; David B. Solit; Gabe S. Sonke; Jean Charles Soria; Parin Sripakdeevong; Natalie H. Stickle; Thomas P. Stricker; Shawn M. Sweeney; Barry S. Taylor; Jelle J. ten Hoeve; Stacy B. Thomas; Eliezer M. Van Allen; Laura J. Van 'T Veer; Tony van de Velde; Harm van Tinteren; Victor E. Velculescu; Carl Virtanen; Emile E. Voest; Lucy L. Wang; Chetna Wathoo; Stuart Watt; Celeste Yu; Thomas V. Yu; Emily Yu; Ahmet Zehir; Hongxin Zhang
Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma
Banu Eskiocak; Elizabeth A. McMillan; Saurabh Mendiratta; Rahul K. Kollipara; Hailei Zhang; Caroline G. Humphries; Changguang Wang; Jose Garcia-Rodriguez; Ming Ding; Aubhishek Zaman; Tracy I. Rosales; Ugur Eskiocak; Michael P. Smith; Jessica Sudderth; Kakajan Komurov; Ralph J. Deberardinis; Claudia Wellbrock; Michael A. Davies; Jennifer A. Wargo; Yonghao Yu; Jef K. De Brabander; Noelle S. Williams; Lynda Chin; Helen Rizos; Georgina V. Long; Ralf Kittler; Michael A. White
Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Non–Small Cell Lung Cancer
Dennis O. Adeegbe; Yan Liu; Patrick H. Lizotte; Yusuke Kamihara; Amir R. Aref; Christina Almonte; Ruben Dries; Yuyang Li; Shengwu Liu; Xiaoen Wang; Tiquella Warner-Hatten; Jessica Castrillon; Guo-Cheng Yuan; Neermala Poudel-Neupane; Haikuo Zhang; Jennifer L. Guerriero; Shiwei Han; Mark M. Awad; David A. Barbie; Jerome Ritz; Simon S. Jones; Peter S. Hammerman; James Bradner; Steven N. Quayle; Kwok-Kin Wong
Epigenetic Identity in AML Depends on Disruption of Nonpromoter Regulatory Elements and Is Affected by Antagonistic Effects of Mutations in Epigenetic Modifiers
Jacob L. Glass; Duane Hassane; Bas J. Wouters; Hiroyoshi Kunimoto; Roberto Avellino; Francine E. Garrett-Bakelman; Olga A. Guryanova; Robert Bowman; Shira Redlich; Andrew M. Intlekofer; Cem Meydan; Tingting Qin; Mame Fall; Alicia Alonso; Monica L. Guzman; Peter J.M. Valk; Craig B. Thompson; Ross Levine; Olivier Elemento; Ruud Delwel; Ari Melnick; Maria E. Figueroa
Author Choice
PAX3–FOXO1 Establishes Myogenic Super Enhancers and Confers BET Bromodomain Vulnerability
Berkley E. Gryder; Marielle E. Yohe; Hsien-Chao Chou; Xiaohu Zhang; Joana Marques; Marco Wachtel; Beat Schaefer; Nirmalya Sen; Young Song; Alberto Gualtieri; Silvia Pomella; Rossella Rota; Abigail Cleveland; Xinyu Wen; Sivasish Sindiri; Jun S. Wei; Frederic G. Barr; Sudipto Das; Thorkell Andresson; Rajarshi Guha; Madhu Lal-Nag; Marc Ferrer; Jack F. Shern; Keji Zhao; Craig J. Thomas; Javed Khan
Modeling Renal Cell Carcinoma in Mice: Bap1 and Pbrm1 Inactivation Drive Tumor Grade
Yi-Feng Gu; Shannon Cohn; Alana Christie; Tiffani McKenzie; Nicholas Wolff; Quyen N. Do; Ananth J. Madhuranthakam; Ivan Pedrosa; Tao Wang; Anwesha Dey; Meinrad Busslinger; Xian-Jin Xie; Robert E. Hammer; Renée M. McKay; Payal Kapur; James Brugarolas
Correction
News in Brief
Research Watch
Apoptosis
Clinical Trials
Drug Evaluation
Drug Resistance
Gene Expression
Immunology
Leukemia
Metabolism
Metastasis
Multiple Myeloma
Prostate Cancer
Transcriptional Regulation
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.